報價延遲最少15分鐘:2025/06/06 01:08 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
38.015 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.98/-1.68
|
|
企業價值
217.64M
|
| 資產負債 |
|
每股賬面淨值
8.76
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/06 01:08 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers. |